Zobrazeno 1 - 10
of 356
pro vyhledávání: '"Harald, Holte"'
Autor:
Baoyan Bai, Jillian F. Wise, Daniel Vodák, Sigve Nakken, Ankush Sharma, Yngvild Nuvin Blaker, Marianne Brodtkorb, Vera Hilden, Gunhild Trøen, Weicheng Ren, Susanne Lorenz, Michael S. Lawrence, Ola Myklebost, Eva Kimby, Qiang Pan-Hammarström, Chloé B. Steen, Leonardo A. Meza-Zepeda, Klaus Beiske, Erlend B. Smeland, Eivind Hovig, Ole Christian Lingjærde, Harald Holte, June Helen Myklebust
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-12 (2024)
Abstract Follicular lymphoma (FL) is the most common indolent type of B-cell non-Hodgkin lymphoma. Advances in treatment have improved overall survival, but early relapse or transformation to aggressive disease is associated with inferior outcome. To
Externí odkaz:
https://doaj.org/article/92e65d15b9924346a5867a14c377ae05
Autor:
Maja Ludvigsen, Amanda Jessica Campbell, Marie Beck Enemark, Trine Engelbrecht Hybel, Marja-Liisa Karjalainen-Lindsberg, Klaus Beiske, Mette Bjerre, Lars Møller Pedersen, Harald Holte, Sirpa Leppä, Judit Meszaros Jørgensen, Bent Honoré
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-4 (2023)
Externí odkaz:
https://doaj.org/article/ab1454cd48054784b05aa97696135a7e
Autor:
Anna Sureda, Lorenzo Falchi, Sirpa Leppa, Joost Vermaat, Harald Holte, Martin Hutchings, Pieternella Lugtenburg, Sven de Vos, Pau Abrisqueta, Marcel Nijland, Reid W. Merryman, Jacob Haaber Christensen, Bjorn Wahlin, Kim Linton, Liwei Wang, Aqeel Abbas, Ali Rana, Syed Quadri, David Belada
Publikováno v:
HemaSphere, Vol 7, p e5547136 (2023)
Externí odkaz:
https://doaj.org/article/327f7aeaa4ac4754846a26ed47c7ba62
Low lymphocyte‐to‐monocyte ratio predicts poor outcome in high‐risk aggressive large B‐cell lymphoma
Publikováno v:
eJHaem, Vol 3, Iss 3, Pp 681-687 (2022)
Abstract Low lymphocyte‐to‐monocyte‐ratio (LMR) has been associated with unfavorable survival in patients with diffuse large B‐cell lymphoma (DLBCL). To date, however, the impact of LMR on survival has not been examined in a uniformly treated
Externí odkaz:
https://doaj.org/article/72bb604df87a4e4bb9377f58707229ac
Autor:
Suvi-Katri Leivonen, Terhi Friman, Matias Autio, Samuli Vaittinen, Andreas Wind Jensen, Francesco d’Amore, Stephen Jacques Hamilton-Dutoit, Harald Holte, Klaus Beiske, Panu E. Kovanen, Riikka Räty, Sirpa Leppä
Publikováno v:
Haematologica, Vol 108, Iss 11 (2023)
Post-transplant lymphoproliferative disorders (PTLD) are iatrogenic immune deficiency-associated lymphoid/plasmacytic proliferations developing due to immunosuppression in solid organ or hematopoietic stem cell allograft patients. PTLD are characteri
Externí odkaz:
https://doaj.org/article/69a955652fe3403f8ef0415aeb247b3d
Autor:
Kathrine T. Isaksen, Renate Galleberg, Maria Adele Mastroianni, Marit Rinde, Leiv Sindre Rusten, Dlawer Barzenje, Frode Ramslien, Oystein Fluge, Marit Slaaen, Peter Meyer, Knut Liestol, Erlend B. Smeland, Ole Christian Lingjarde, Harald Holte, Marianne Brodtkorb
Publikováno v:
Haematologica, Vol 108, Iss 9 (2023)
The International prognostic Index (IPI) is the most widely used clinical prediction model for diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), but may be subop
Externí odkaz:
https://doaj.org/article/48c31be81197421d9130d1bd222c9056
Autor:
Kathrine T. Isaksen, Klaus Beiske, Erlend B. Smeland, Judit Jørgensen, Marianne Brodtkorb, June Helen Myklebust, Mats Jerkeman, Leo Meriranta, Marja‐Liisa Karjalainen‐Lindsberg, Sirpa Leppä, David W. Scott, Harald Holte, Yngvild Nuvin Blaker
Publikováno v:
eJHaem, Vol 2, Iss 1, Pp 104-108 (2021)
Externí odkaz:
https://doaj.org/article/065690fb5d4347f098331a06996ed6e6
Autor:
Knut Smeland, Harald Holte, Unn-Merete Fagerli, Hanne Bersvendsen, Marianne J. Hjermstad, Jon H. Loge, Klaus Murbrach, Marianne D. Linnsund, Oystein Fluge, Jo S. Stenehjem, May B. Lund, Stein Kvaloy, Cecilie E. Kiserud
Publikováno v:
Haematologica, Vol 107, Iss 11 (2022)
Lymphoma survivors after high-dose therapy with autologous stem-cell transplant (HDT-ASCT) are at risk of several late effects, which might impair their health-related quality of life (HRQoL). We assessed the total late effect burden in this populati
Externí odkaz:
https://doaj.org/article/5a85605680014758bb80d78a43e7fb73
Autor:
Joshua P. Entrop, Caroline E. Weibull, Karin E. Smedby, Lasse Hjort Jakobsen, Andreas K. øvlisen, Daniel Molin, Ingrid Glimelius, Anna Marklund, Harald Holte, Alexander Fosså, Knut B. Smeland, Tarec Christoffer El-Galaly, Sandra Eloranta
Publikováno v:
HemaSphere, Vol 6, Pp 30-30 (2022)
Externí odkaz:
https://doaj.org/article/d3d0c4d8d34e4a6c808551f2be0d6e6b
Autor:
Michael R. Bishop, Richard T. Maziarz, Edmund K. Waller, Ulrich Jäger, Jason R. Westin, Joseph P. McGuirk, Isabelle Fleury, Harald Holte, Peter Borchmann, Christopher del Corral, Ranjan Tiwari, Özlem Anak, Rakesh Awasthi, Lida Pacaud, Vadim V. Romanov, Stephen J. Schuster
Publikováno v:
Blood Advances, Vol 3, Iss 14, Pp 2230-2236 (2019)
Abstract: Tisagenlecleucel demonstrated high rates of durable responses in adult patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) in the JULIET trial. Most patients (92%) received bridging therapies to control disease af
Externí odkaz:
https://doaj.org/article/f864faf1321a4cc5a02dee8d46be9fc7